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Abstract 
 
The human version of the DPY-30 protein is homologous to the DPY-30 
protein in Caenorhabditis elegans (nematode), along with other DPY-30 
homologous proteins in other organisms.  This protein is involved in dosage 
compensation of X-linked genes, balancing the levels of expression of these 
genes between the sexes.  The mechanism by which the balancing is carried out 
varies from organism to organism.  For example, in C. elegans hermaphrodites 
(XX), transcript levels of the X-linked genes are cut in half.  In Drosophila, the 
genes on the male’s (XY) X chromosome are transcribed at twice the rate of the 
female’s (XX) genes.  In human females (XX), one of the X chromosomes in each 
cell is inactivated at random.  If DPY-30 is absent from the organism, this can 
lead to XX-lethality.  In humans, DPY-30 forms a complex with four other 
proteins:  MLL1, WDR5, RbBP5, and ASH2L.  This complex is responsible for 
methylating histones, particularly histone H3 Lysine 4 (H3K4).  Methylation of 
H3K4 promotes transcription of genes.  Similar complexes are found in other 
organisms.  The fact that these proteins are conserved across species indicates 
how important they are.  Within the complex itself, DPY-30 binds to ASH2L.  The 
amino acids responsible for this interaction, however, remain unknown.  The 
purpose of this project is to identify which amino acids are responsible for the 
binding between DPY-30 and ASH2L.  A further extension of this project is its 
potential anticancer applications.  When MLL1 is activated improperly and forms 
the complex, it can lead to the development of Acute Lymphoblastic Leukemia 
(ALL).  It is thought that if the complex were to be disrupted and broken apart or 
prevented from forming, the cancerous cell would stop proliferating and die.  If 
the amino acids responsible for the DPY-30 and ASH2L binding were identified, a 
drug or peptide could be designed to bind to DPY-30 or ASH2L, preventing it 
from completing formation of the MLL1 Core Complex.   
The first step in this experiment was to compare DPY-30 homologs from 
different species, to see if any amino acid residues were either completely 
conserved or mostly conserved.  Once the conserved residues were identified, 
one was selected to change, Arginine (R) 54.  It was changed to an Alanine (A).  
Three other single amino acid mutations were made:  Arginine (R) 76, Leucine (L) 
66, and Leucine (L) 65.  All three were changed to Alanines.  Once primers with 
the correct mutation were made, the DNA sequence was put through PCR and 
transformed into E. coli cells.  The DNA was extracted, sequenced, and 
transformed into another E. coli strain.  A large culture was grown, expression of 
protein was induced, the cells were lysed, and the protein was collected.  Once 
the mutant protein was purified, it was subjected to multiple tests to determine 
its binding affinity for ASH2L.  For the R54A mutant, the binding interactions 
were weakened, but not completely inhibited.  For the L66A mutant, there was 
no measurable effect on the binding interactions.  It was concluded that Arginine 
54 was a much more important residue than Leucine 66, as far as binding affinity 
was concerned.  
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Capstone Project Body 
Introduction 
Human DPY-30 (dumpy-30) is a homolog of DPY-30 found in 
Caenorhabditis elegans.  It is found in the nucleus and is expressed in all human 
tissues.  DPY-30 is about 22.4 kiloDaltons (kD) and is a homodimer (Wang et al, 
2009).  The two identical monomers are each made up of two helical subunits 
(Wang et al, 2009).  This protein earned its name from experiments in which 
mutations in the protein resulted in a “dumpy” phenotype in the organism, in 
this case C. elegans (Hsu and Meyer, 1994).  The human version of the protein is 
a vital component of dosage compensation machinery and loss of DPY-30 activity 
results specifically in XX-lethality (Dong et al, 2005).  Dosage compensation is a 
regulatory process that functions at the chromosome level to balance the levels 
of expression of X-linked genes between the sexes (Hsu et al, 1995).  Otherwise, 
the sex with multiple X chromosomes would receive a two-fold dose of the X-
linked genes compared to the other sex, which leads to XX-specific lethality 
(Dong et al, 2005).  This condition, for example, affects C. elegans 
hermaphrodites (XX), Drosophila females (XX), and female mammals (XX) (Hsu et 
al, 1995).  Even though the end result is the same, regulation of these X-linked or 
sex-linked genes, however, is carried out differently from one species to another.  
In C. elegans, the transcript levels produced by each X chromosome in XX 
hermaphrodites are halved to equal the transcript levels of the X in males (XO) 
(Dong et al, 2005).  In Drosophila, the X-linked genes in males (XY) are 
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transcribed at twice the rate as the two X chromosomes in females (XX) (Dong et 
al, 2005).   
In female mammals (XX), one of the X chromosomes is randomly 
inactivated so that the X-linked gene expression level matches that of the males 
(XY) (Dong et al, 2005).  This leads to the formation of Barr bodies.  A Barr body 
is the term used to describe the highly condensed, inactivated X chromosome, 
which is unable to have any of its genes transcribed and/or expressed.  In certain 
animals, DPY-30 is used for other developmental processes:  normal body size, 
mating behavior, correct tail morphology, and coordinated movement (Hsu et al, 
1995).  The homolog of DPY-30 found in yeast functions as a member of the 
histone 3 lysine 4 methylation complex, which is the key part of the epigenetic 
transcriptional control mechanism (Dong et al, 2005).  Epigenetics refers to any 
heritable change in gene expression, meiotic and/or mitotic, that is not actually 
coded for in the DNA sequence of an organism (Egger et al, 2004).  In humans, 
DPY-30 is able to form a complex with four other proteins, Mixed Lineage 
Leukemia protein-1 (MLL1), ASH2L, WDR5, and RbBP5 (Crawford and Hess, 
2006).  ASH2L stands for absent, small, homeotic discs-2-like, WDR5 stands for 
WD repeat protein-5, and RbBP5 stands for retinoblastoma-binding protein 5 
(Patel et al, 2008).  The MLL1 complex is necessary for methylation of histones, 
in particular histone H3 Lysine 4 (H3K4) (Crawford and Hess, 2006).  This 
methylation is important for allowing transcription of target genes to occur 
within cells (Crawford and Hess, 2006).  MLL1 is also vital to the regulation of hox 
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genes in hematopoiesis and development (Patel et al, 2008).  The fact that these 
core components are conserved across species speaks volumes about their 
importance in cellular activity (Crawford and Hess, 2006).  Within the MLL1 core 
complex itself, DPY-30 binds specifically to ASH2L (South et al, 2009), yet the 
identity of the binding site remains unknown (see Figure 1).  
 
Another aspect of this project is its potential therapeutic applications.  
The MLL1 gene itself has a tendency to undergo reciprocal translocations 
(Srinivasan et al, 2004), where the gene breaks at a cleavage point and rejoins 
with another gene from another chromosome.  Another occurrence is that MLL1 
Figure 1:  A cartoon model of the theoretical 
structure of the MLL1 Core Complex.  (Figure 
obtained from Patel et al, June 25, 2009)  
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can undergo partial tandem duplications (MLL-PTD), where certain parts of the 
gene are duplicated.  Both situations result in fusion proteins, which have been 
directly linked to leukemogenesis, specifically Acute Lymphoblastic Leukemia 
(ALL) (Srinivasan et al, 2004).  When functioning normally, MLL1 is critical for 
hematopoiesis and the development of the organism, as the loss of function 
results in death.  The involvement of this protein in cancer is the ultimate driving 
force behind this project.  These MLL-PTD proteins still end up forming the 
complex with the other four proteins.  The idea is that if the formation of the 
complex was disrupted, the cancerous cell would not be as active or as potent, 
which would help in treating people with the disease.  This is why discovering 
the amino acids that make up the binding site between DPY-30 and ASH2L is so 
important.  A peptide or drug could then be used to block formation of the 
complex.  This same strategy could be employed with any of the other binding 
sites within the complex.   
The purpose of my research is to determine which amino acid residues 
are involved in the binding process between the DPY-30 protein and the ASH2L 
protein.  A sequence alignment will be performed using various homologs of 
DPY-30 in order to determine which residues have been conserved over the 
course of evolution.  Such homologs include the DPY-30 homolog in C. elegans 
and the Saf19p protein, the DPY-30 homolog in S. cerevisiae (Dong et al, 2005).  
The rationale behind this is that if certain residues have been completely or 
mostly conserved, they must have some importance for the function of the 
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protein and/or the overall survival of the cell/organism.  Once these conserved 
residues have been identified, wild type DPY-30 protein will be expressed and 
purified.  Then the conserved residues will be systematically mutated one at a 
time, via site-directed mutagenesis.  The mutant DPY-30 proteins will be purified 
and an assay will be performed after each individual mutation to determine how 
it affects the binding of DPY-30 to ASH2L.  To yield qualitative results, Native 
(agarose) gel assays will be performed to observe if binding is affected.  
Analytical Ultracentrifugation (AUC) will be used to obtain quantitative results 
regarding to the binding affinity the mutated DPY-30 has for ASH2L.  Additional 
analysis of the mutant might include an enzymatic activity assay to see what 
effect the mutant protein has on the ability of the MLL1 Core Complex to 
methylate H3K4.  This project is expected to provide some insight into the 
specific role that DPY-30 plays in the MLL1 core complex.   
 
METHODS 
Sequence Alignment and Protein Expression and Purification 
DNA sequences of DPY-30 homologs/DPY-30-like proteins in 13 different 
organisms were collected and compared using the National Center for 
Biotechnology Information’s database (NCBI).  A sequence alignment was 
performed, using Clustal W (Clustal 2.0.8, 2008), to identify completely 
conserved or highly conserved amino acid residues (see Figure 15, Appendix A).  
The organisms used for the alignment were Caenorhabditis elegans (nematode) 
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(Accession number:  Q10661), Saccharmyces cerevisiae (Baker’s yeast) 
(Accession number:  NP_010757), Mus musculus (house mouse) (Accession 
number:  Q99LT0), Homo sapiens (human) (Accession number:  Q9C005), Bos 
taurus (cattle) (Accession number:  AAI11635), Ornithorhynchus anatinus 
(platypus) (Accession number:  XP_001508793), Monodelphis domestica (gray 
short-tailed opossum) (Accession number:  XP_001371479), Gallus gallus (red 
jungle fowl) (Accession number:  XP_419530), Strongylocentrotus purpuratus 
(purple urchin/purple sea urchin) (XP_001189793), Pan troglodytes 
(chimpanzee) (Accession number:  XP_001164263 and XP_00164291), Apis 
mellifera (honey bee) (Accession number:  XP_001120012), Macaca mulatta 
(rhesus monkey) (Accession number:  XP_001105547 and XP_001105621), and 
Canis lupus familiaris (dog) (Accession number:  XP_532923).  The 54
th
 amino 
acid, Arginine, was chosen as the first target for site-directed mutagenesis.  The 
forward and reverse primers with the appropriate mutation were designed and 
ordered.  The primer sequences were amplified using Polymerase Chain Reaction 
(PCR).  The reaction mixtures were put on ice for 2 minutes to cool them below 
37°C and then subjected to Dpn I restriction enzyme digestion to get rid of any 
parental or nonmutated DNA.  Each amplification reaction was incubated at 37°C 
for 1 hour to allow for proper digestion.  The mutated DNA was then 
transformed into Escherichia coli DH5α cells, which were then incubated on 
Lysogeny Broth (LB) agar plates.  Once colonies were formed, the blue ones, 
which represented successful transformations, were selected to use for growing 
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an overnight 5mL culture in LB broth/media.  Five microliters of 1000x 
carbenicillin were added to each tube used and the tubes were incubated at 
37°C in a shaker, making sure the cap was slightly loose to allow oxygen to reach 
the cells.  Only one colony was used for inoculating each tube.  Once the cultures 
were grown, a Miniprep was performed to lyse the cells and extract the DNA.  
The DNA was stored at -20°C.   
The concentration of each DNA sample was measured and a sample of 
each DNA sequence, along with the T7 primer, was sent to be sequenced at 
SUNY Upstate Medical University to check for sequence accuracy.  Five 
microliters of sample and one microliter of T7 primer (1 picomole/microliter) 
were mixed in a PCR tube.  Once it was confirmed that the site was successfully 
mutated from an Arginine into an Alanine, while maintaining the wild-type 
sequence throughout the rest of the DNA, the mutant DNA was then 
transformed into the Rosetta 2 PlysS strain of E. coli.  A small scale culture was 
grown using Terrific Broth II (TBII, 50mL).  Fifty microliters each of carbenicillin 
(50mg/mL stock solution) and 1x-chloramphenicol (20mg/mL stock solution) 
were added to the culture.  Then 10mL from the small scale culture were used to 
start a large scale (1L) culture.  Expression of the protein was induced through 
the addition 1 mL of Isopropyl β-D-1-thiogalactopyranoside (IPTG, 1M stock 
solution).  The large flasks were placed on a shaker and incubated at 37°C.  Once 
the proper levels of growth were achieved, the cultures were incubated at 4°C 
for 1 hour.  The cells were then centrifuged and stored as a pellet in the -80°C 
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freezer, if necessary.  The pellet was thawed, if necessary, and was broken open 
using Lysis buffer and a Microfluidizer.   
 
RESULTS 
The mutant protein was collected and purified through a series of steps.  
The first was a Nickel Affinity Chromatography column (see Figures 2 and 3).   
           
 
 
 
This technique is also called a His-trap run because DPY-30 has a His-tag (six 
histidines) attached to its N-terminus.  This structure has an affinity for Nickel, 
allowing the protein to bind to the column, trapping it there, while other 
proteins were washed away.  The fractions with the protein were collected and 
run on an SDS polyacrylamide gel to check the protein’s purity.  The gel was 
stained (coomassie Stain, 30 seconds in microwave, 10 minutes on rocker) and 
Figure 2:  DPY-30 R54A His-trap Run 1.  The R54A protein sample (lanes 1-8) after its 
first nickel affinity chromatography run.  There are a lot of impurities (other proteins) 
present.  The protein marker (PM) or ladder is a set of standards with known 
molecular weights and is used as a reference point for other proteins run on the gel.  
The crude extract (CE) is taken from the protein sample prior to purification.    
  1       2       3       4      5     6       7      8      CE   PM 
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then destained (Destain 1
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present were combined and 
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Figure 3:  DPY-30 L66A His
(lanes 1-13) after its first nickel affinity chromatography run.  
Notice the large amount of impurities present.  
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Figure 4:  DPY-30 R54A His
after its second nickel chromatography run.  
impurities present.  The crude extract and protein marker were run alongside 
the samples to use as reference points.  
Figure 5:  DPY-30 L66A His
sample (lanes 1-12) 
run.  There are considerably fewer impurities than after the 
first run.  The crude extract for the second
the protein after dialysis is completed.  
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The fractions were combined and the sample was concentrated down to 5 or 
less milliliters, if necessary.  The concentration of the protein was measured 
using the Nanodrop spectrophotometer and then the extinction coefficient 
(0.397) was calculated using the NCBI website, which then led to the calculation 
of the true concentration of the protein.  The sample was then run on a size 
exclusion chromatography column.  The fractions were then analyzed using SDS 
PAGE (see Figures 6 and 7) and the staining/destaining procedure used above.  
Some samples were placed in the -80°C freezer, while another was used for 
performing analysis.   
 
 
 
Figure 6:  DPY-30 R54A Gel Filtration Run.  
The R54A protein sample (lanes 1-6) after its 
size exclusion chromatography run.  The 
sample is virtually impurity free.   
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the R54A site-directed mutagenesis.  Other areas of research could include 
determining the mutant’s effect on the activity of the MLL1 core complex and/or 
what the structure of DPY-30 is while bound to ASH2L.   
The R54A Mutant Negatively Affects DPY-30’s Interactions With ASH2L While the 
L66A Mutant Does Not 
The sequence alignment identified 13 completely conserved sites 
between the DPY-30 homologs/DPY-30-like proteins (see Figure 15, Appendix A).  
Based on the native gel assay and the AUC data, the R54A DPY-30 mutant was 
still able to bind with wild-type ASH2L.  The Native gel showed slight differences 
between the lane with the wild-type DPY-30 and ASH2L (lane 3) and the lane 
with the mutant DPY-30 and ASH2L (lane 5).  There was a greater amount of free 
ASH2L left in the lane with the mutant DPY-30 than in the lane with wild-type 
DPY-30 (see Figure 9).  This implies that the binding was weakened as a result of 
the mutation.   
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The AUC results showed that the mutant protein had a similar 
sedimentation coefficient to the wild-type protein for its main peak, but there 
were also additional peaks present for the mutant protein that were absent from 
the wild-type protein (see Figure 10a).  The peak that normally corresponds to 
wild-type ASH2L binding with wild-type DPY-30 shifted when the R54A DPY-30 
mutant was run on the AUC with wild-type ASH2L (see Figure 10b).   
 
 
 
 
 
 
Figure 9:  DPY-30 R54A Native 
gel assay.  Lanes, from left to 
right – wild-type DPY-30 (lane 
1), wild-type ASH2L (lane 2), 
wild-type DPY-30 interacting 
with wild-type ASH2L (lane 3), 
mutant DPY-30 (lane 4), and 
mutant DPY-30 interacting with 
wild-type ASH2L (lane 5).  In the 
last lane, there is more unbound 
ASH2L leftover with the mutant 
DPY-30 than in the lane with the 
wild-type DPY-30.  
Concentrations of ASH2L, wild-
type DPY-30, and mutant DPY-
30 were 0.5 milligrams/milliliter.  
These results suggest that the 
R54A mutant is still able to bind 
with wild-type ASH2L but that 
the interaction is weaker.   
DPY-30 R54A 
Wt ASH2L 
DPY-30 R54A +  
Wt ASH2L 
Wt DPY-30 +  
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Figure 10a (top):  DPY-30 R54A SV AUC.  The AUC data for the DPY-30 R54A mutant at three 
different concentrations:  1.0 milligrams/milliliter, 0.6 milligrams/milliliter, and 0.2 
milligrams/milliliter.  The main peak for all three runs has a sedimentation coefficient of 1.3.  
Wild-type DPY-30 has about the same sedimentation coefficient.  The wild-type protein does 
not have any additional peaks, however, as opposed to the mutant protein.  These additional 
peaks might be caused by other conformations of the protein, which were most likely brought 
on by the mutation that was made.  These results suggest that mutation affects DPY-30’s ability 
to fold properly, which could result in multiple conformations.   
Figure 10b (bottom):  The AUC data for wild-type DPY-30 by itself, wild-type ASH2L by itself, wt 
DPY-30 + wt ASH2L, and wt ASH2L + DPY-30 R54A. The concentration for all the proteins 
analyzed was 0.5 milligrams/milliliter.  The peak for the mutant complex has a different 
sedimentation coefficient than the wild-type complex.  This result backs up the result from the 
native gel assay (above) suggesting that the mutant DPY-30 is still able to bind to wt ASH2L but 
that the interaction is not quite the same as compared to the wild-type complex.   
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This conclusion was confirmed by the AUC results,
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Figure 12:  DPY-30 L66A 
gel assay.  Lanes, fro
right – wild-type DPY
wild-type ASH2L (lane 2)
type DPY-30 interacting with wild
type ASH2L (lane 3)
30 (lane 4), and mutant DPY
interacting with wild
(lane 5).  There are about
amounts of ASH2L bound with the 
mutant DPY-30 as there is with 
the wild-type DPY-30.  
Concentrations of ASH2L, wild
type DPY-30, and mutant DPY
were 0.5 milligrams/milliliter.  
These results suggest that the
L66A mutant binds to ASH2L as 
well as wild-type DPY
Figure 13:  DPY
AUC.  AUC data for Wild
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DISCUSSION   
The identification of the conserved residues implied that they were of 
some importance.  If not, they would have been less likely to be conserved over 
the course of evolution across different species.  This led to the belief that 
mutating one of them would have some negative effect on DPY-30’s ability to 
dimerize and/or bind with ASH2L.  The R54A mutation appears to be somewhat 
Figure 14a (top):  DPY-30 L66A SV AUC.  AUC data for DPY-30 L66A, at 0.125mg/mL.   
Figure 14b (middle):  AUC data for DPY-30 L66A, at 0.25mg/mL.   
Figure 14c (bottom):  AUC data for DPY-30 L66A, at 0.5mg/mL.  All three samples 
have peaks at 1.31, which is about the sedimentation coefficient for wild-type DPY-
30.  There are also no additional peaks of any significance present.  This suggests 
that the mutation has no effect on the conformation of the protein.   
A 
B 
C 
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important regarding the binding sites between DPY-30 and ASH2L.  This 
mutation additionally seems to affect DPY-30’s ability to fold properly, as the 
mutant by itself had an altered sedimentation coefficient than its wild-type 
counterpart.  One possible explanation is that the mutation caused different 
conformations of the protein to form, such as an alternate dimer or perhaps 
even a tetramer.  Sedimentation coefficients are dependent upon both the mass 
and shape/conformation of the molecule being analyzed.  In this case, both 
variables were changed, but the conformation probably had a greater effect than 
the mass.  The mutant DPY-30 also appears to affect the enzymatic activity of the 
WRAD complex.  The inactivity of the WRAD complex with the H3 peptide 
suggests that DPY-30 might play an important role in the enzymatic activity of 
this complex.   
The L66A mutant, it was concluded, did not seem to play a significant 
role, or any role, in either DPY-30’s ability to fold properly or DPY-30’s ability to 
bind to ASH2L.  There were no additional peaks present in the mutant AUC data, 
suggesting that no alternate conformations of the protein were formed.  The 
difference in mass between the mutant and wild-type was also not enough on its 
own to illicit a change in the sedimentation coefficient.   
The results of these experiments illustrated that Arginine 54 was located 
along the DPY-30 dimer interface as well as the DPY-30-ASH2L interface, 
whereas Leucine 66 was not.  This might explain the two differing results 
between the mutants.  Another explanation might be the nature of the 
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substitution that was made in each mutant.  Arginine is a large, positively 
charged molecule while Alanine is a small, neutral, and hydrophobic molecule.  
Leucine is a large molecule also, but is neutral and hydrophobic.  If time had 
permitted, an enzymatic assay would have been performed with the L66A 
mutant, even though it most likely would not have shown any significant 
difference in activity from the wild-type MLL complex.  It would have also been 
beneficial to also test the other two mutants that were made, L65A and R76A, to 
see what kind of results these proteins yielded.   
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Appendix A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15:  Sequence Alignment of DPY-30 
homologs.  The 13 completely conserved amino 
acids have a star beneath their column and are 
boxed in.   
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Appendix B 
Buffer Preparation 
50 mg/ml stock solution of Carbenicillin:  10mL doubly deionized water (ddH20) + 500mg 
Carbenicillin 
1x-Chloramphenicol (20mg/mL):  10mL Ethanol + 200mg 1x-Chloramphenicol 
1M stock solution of IPTG:  10mL ddH20 + 2.3831g IPTG  
Column Buffer (4L, pH 7.4):  50mM Tris (24.228g), 300mM NaCl (70.128g), 3mM DTT 
(1.851036g), 30mM Imidazole (8.1696g) + ddH20 
Elution Buffer (500mL, pH 7.4):  50mM Tris (3.0285g), 300mM NaCl (8.766g), 3mM DTT 
(0.2313795g), 500mM Imidazole (17.02g) + ddH20 
Lysis Buffer:  50mL of Column Buffer + 0.1mM Phenylmethanesulfonylfluoride (PMSF) + 
1 Ethylenediaminetetraacetic acid (EDTA)-free protease inhibitor cocktail tablet 
Destain 1 (2L):  50% 100 proof Ethanol (1L) + 10% Acetic Acid (200mL) + ddH20 
Destain 2 (2L):  5% 100 proof Ethanol (100mL) + 10% Acetic Acid (200mL) + ddH20 
Buffer A (2L, pH 8.5):  25mM Tris-HCl (3.0285g) + 19.2mM Glycine (1.42633g) 
Agarose gel (0.8%):  50mL Buffer A + 0.4g Agarose 
LB (100mL):  3 pellets + ddH20 
TBII (50mL):  2.5g TBII + ddH20 
Coomassie Stain (2.5L):  7g Brilliant Blue R + 250mL Acetic Acid + 1125mL 100 proof 
Ethanol + 1125mL ddH20 
t-CEP Buffer (600mL, pH 7.5):  20mM Tris-Cl (1.45368g Tris) + 300mM NaCl (10.5192g) + 
1μM ZnCl2 (6μL) + 1mM t-CEP (0.1770g) + ddH20 
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Captsone Summary 
The human version of the DPY-30 protein is homologous, or very closely 
related, to the DPY-30 protein in Caenorhabditis elegans, along with other DPY-
30 homologous proteins in other organisms.  This protein is involved in dosage 
compensation of sex-linked or X-linked genes, balancing the levels of expression 
between the sexes.  The mechanism by which the balancing is carried out varies 
from organism to organism.  For example, in C. elegans, hermaphrodites are XX 
and the transcript levels of the X-linked genes are cut in half.  In Drosophila (fly), 
the genes on the male’s (XY) X chromosome are transcribed at twice the rate of 
the female’s (XX) genes.  Transcription is the process of converting a DNA 
sequence into the corresponding mRNA.  In human females (XX), one of the X 
chromosomes in each cell is inactivated at random.  The inactivated X 
chromosome becomes highly condensed, forming what is called a Barr body.  If 
DPY-30 is not functioning properly or the protein is absent from the organism, 
this can lead to XX-lethality (death).  Death is caused by the overdose of the 
proteins encoded by the X chromosome genes.  This protein is also involved in 
developmental processes in animals that are XO.  Some of these processes 
include mating behavior, normal body size, correct tail morphology, and 
coordinated movement.   
In humans, DPY-30 forms a complex with four other proteins:  MLL1, 
WDR5, RbBP5, and ASH2L.  This complex is responsible for methylating histones, 
particularly histone H3 Lysine 4 (H3K4).  Lysine is one of the twenty amino acids 
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used as the building blocks for proteins.  A histone is a protein that interacts with 
DNA.  There are 5 types of histones:  H1, H2A, H2B, H3, and H4.  The last four 
histones form an octamer (2 copies of each individual histone) that DNA strands 
wrap around to help condense them.  This is called a nucleosome.  H1 serves as a 
linker molecule between nucleosomes.  Methylation refers to adding a methyl 
group (-CH3) to a molecule.  Methylation of H3K4 promotes transcription of 
genes, some of which are necessary for the organism’s survival.  Methylation of 
DNA is an example of epigenetic regulation, meaning it can bring about changes 
in the expression of certain genes without altering the DNA sequence of the 
organism.  Epigenetics refers to any heritable change in gene expression, meiotic 
and/or mitotic, that is not actually coded for in the DNA sequence of an 
organism.  These changes are heritable because they can be passed on to the 
offspring of an organism.  Similar complexes are found in other organisms.  The 
fact that these proteins are conserved across species indicates how important 
they are.  Within the complex itself, DPY-30 binds to ASH2L.  The amino acids 
responsible for this interaction, however, remain unknown.  The purpose of this 
project is to identify which amino acids are responsible for the binding between 
DPY-30 and ASH2L.   
A further extension of this project is its potential anticancer applications.  
The MLL1 gene had been found to break apart and rejoin with either other MLL1 
genes or other genes.  This leads to the production of abnormal fusion proteins.  
These fusion proteins lead to improper activity of MLL1.  When MLL1 is activated 
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improperly and forms the complex, it can lead to the development of Acute 
Lymphoblastic Leukemia (ALL).  It is thought that if the complex were to be 
disrupted and broken apart or prevented from forming, the cancerous cell would 
stop proliferating and die.  If the amino acids responsible for the DPY-30 and 
ASH2L binding were identified, a drug or peptide, which is a chain of amino acids, 
could be designed to bind to DPY-30 or ASH2L, preventing it from completing 
formation of the MLL1 Core Complex.   
The first step in this experiment was to compare DPY-30 homologs from 
different species, to see if any amino acid residues were either completely 
conserved or mostly conserved.  These conserved residues, or amino acids, 
would most likely be very important to DPY-30’s ability to function.  A conserved 
residue is one that is the same in all or most of the different species when 
looking at a similar protein in those different organisms.  Once the conserved 
residues were identified, one was selected to change, Arginine (R) 54.  It was 
changed to an Alanine (A).  Three other single amino acid mutations were made:  
Arginine (R) 76, Leucine (L) 66, and Leucine (L) 65.  All three were changed to 
Alanines.  Arginine, Leucine, and Alanine are three more of the twenty amino 
acids.  Once primers, short segments of DNA, with the correct mutation were 
made, the DNA sequence was put through Polymerase Chain Reaction (PCR) and 
transformed into E. coli cells.  PCR amplifies a specific segment of DNA, while a 
transformation is the term used when foreign DNA is being introduced into an 
organism.  The DNA was extracted, sequenced, and transformed into another E. 
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coli strain.  The DNA was extracted by breaking open the cells.  Sequencing refers 
to determining the exact sequence of a DNA segment to make sure it is correct.  
In this case, the DNA was being checked for the presence of the correct 
mutation, while the rest of the sequence was wild-type, or not mutated.  A large 
culture of bacteria was grown, expression of protein was induced, the cells were 
lysed or broken open, and the protein was collected.  Once the mutant protein 
was purified, it was subjected to multiple tests to determine its binding affinity 
for ASH2L.  The purification served to isolate the mutant DPY-30 protein from all 
the other proteins present in the cells, so that experiments could be run on a 
fairly pure sample.  Otherwise, these other proteins might interfere with the 
results, making them unreliable and difficult to interpret.  For the R54A mutant, 
the binding interactions were weakened, but not completely inhibited.  For the 
L66A mutant, there was no measurable effect on the binding interactions and 
the proteins interacted with each other as they normally do.  It was concluded 
that Arginine 54 was a much more important residue than Leucine 66, as far as 
binding affinity was concerned.   
It would have been interesting to examine the results from the other two 
mutants that were generated, if there had been time to test them.  It certainly 
seems that R54 is one of the amino acids involved in the binding of ASH2L by 
DPY-30, while L66 is not.  If time had permitted testing of the other two 
mutations, as well as making additional mutations, more of the amino acids 
responsible for the binding might have been identified.  This could have 
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potentially led to complete identification of all the necessary amino acids, which 
in turn could have led to total inhibition of binding between the two proteins.  
This might have been achieved by changing all the important amino acids into 
Alanines or just deleting the important amino acids.  If complete inhibition of 
binding was achieved, a peptide or drug with the appropriate sequence could 
have been designed and tested to see how well it interacted with DPY-30 and, 
subsequently, blocked ASH2L from binding with DPY-30.   
